UniProt P25440
Bromodomain-containing protein 2 (P25440)
Bromodomain-containing protein 2 (UniProt P25440): 185 experimental structures and 1 predicted model on GenesisL1, 76 ligands bound, 67 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- P25440
- Protein
- Bromodomain-containing protein 2
- Experimental structures
- 185
- Predicted models
- 1
- Ligands
- 76
- Pockets
- 67 · 12 records with a druggable one
Structures
186 records of P25440 in the MolNFT archive: 185 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1X0J | Crystal structure analysis of the N-terminal bromodomain of human Brd2 | x-ray diffraction | A, B, C | — | — |
| 1X0J | Crystal structure analysis of the N-terminal bromodomain of human BRD2 | x-ray diffraction | A, B, C | — | — |
| 2DVQ | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVQ | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVR | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVR | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVS | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVS | Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated… | x-ray diffraction | A, B, C | — | — |
| 2DVV | Crystal structure of the second bromodomain of the human Brd2 protein | x-ray diffraction | A | — | — |
| 2DVV | Crystal structure of the second bromodomain of the human BRD2 protein | x-ray diffraction | A | — | — |
| 2E3K | Crystal structure of the human Brd2 second bromodomain in complexed with the acetylated histone H4… | x-ray diffraction | A, B, C, D | — | — |
| 2E3K | Crystal structure of the human BRD2 second bromodomain in complexed with the acetylated histone H4… | x-ray diffraction | A, B, C, D | — | — |
| 2G4A | Solution structure of a Bromodomain from RING3 protein | solution nmr | A | — | — |
| 2G4A | Solution structure of a bromodomain from RING3 protein | solution nmr | A | — | — |
| 2YDW | Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GW841819X | x-ray diffraction | A, B, C | — | — |
| 2YDW | Crystal structure of the first bromodomain of human BRD2 with the inhibitor GW841819X | x-ray diffraction | A, B, C | — | — |
| 2YEK | Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GSK525762 (IBET) | x-ray diffraction | A, B, C | — | — |
| 2YEK | Crystal structure of the first bromodomain of human BRD2 with the inhibitor GSK525762 (ibet) | x-ray diffraction | A, B, C | — | — |
| 3AQA | Crystal structure of the human BRD2 BD1 bromodomain in complex with a BRD2-interactive compound… | x-ray diffraction | A, B, C | — | — |
| 3AQA | Crystal structure of the human BRD2 BD1 bromodomain in complex with a BRD2-interactive compound… | x-ray diffraction | A, B, C | — | — |
| 4A9E | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9E | N-terminal bromodomain of human BRD2 with 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9F | N-terminal bromodomain of human BRD2 with 1-methylpyrrolidin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9F | N-terminal bromodomain of human BRD2 with 1-methylpyrrolidin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9H | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one | x-ray diffraction | A, B, C | — | — |
| 4A9H | N-terminal bromodomain of human BRD2 with 1-(2-methyl-1,2,3,4- tetrahydroquinolin-1-YL)ETHAN-1-one | x-ray diffraction | A, B, C | — | — |
| 4A9I | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9I | N-terminal bromodomain of human BRD2 with 3-methyl-1,2,3,4- tetrahydroquinazolin-2-one | x-ray diffraction | A, B, C | — | — |
| 4A9J | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(4-hydroxyphenyl) acetamide | x-ray diffraction | A, B, C | — | — |
| 4A9J | N-terminal bromodomain of human BRD2 with N-(4-hydroxyphenyl) acetamide | x-ray diffraction | A, B, C | — | — |
| 4A9M | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopentyl-5-(3,5… | x-ray diffraction | A, B, C | — | — |
| 4A9M | N-terminal bromodomain of human BRD2 with N-cyclopentyl-5-(… | x-ray diffraction | A, B, C | — | — |
| 4A9N | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopropyl-5-(3,5… | x-ray diffraction | A, B, C | — | — |
| 4A9N | N-terminal bromodomain of human BRD2 with N-cyclopropyl-5-(3,5… | x-ray diffraction | A, B, C | — | — |
| 4A9O | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5 ethyl-3-methyl-4-phenyl-1, 2-oxazole | x-ray diffraction | A, B, C | — | — |
| 4A9O | N-terminal bromodomain of human BRD2 with 5 ethyl-3-methyl- 4-phenyl-1,2-oxazole | x-ray diffraction | A, B, C | — | — |
| 4AKN | N-Terminal Bromodomain of Human BRD2 With tbutyl-phenyl-amino… | x-ray diffraction | A, B, C | — | — |
| 4AKN | N-terminal bromodomain of human BRD2 with tbutyl-phenyl-amino… | x-ray diffraction | A, B, C | — | — |
| 4ALG | N-Terminal Bromodomain of Human BRD2 With IBET-151 | x-ray diffraction | A | — | — |
| 4ALG | N-terminal bromodomain of human BRD2 with ibet-151 | x-ray diffraction | A | — | — |
| 4ALH | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3,5 dimethyl-4-phenyl-1,2- oxazole | x-ray diffraction | A, B, C | — | — |
| 4ALH | N-terminal bromodomain of human BRD2 with 3,5 dimethyl-4-phenyl-1,2- oxazole | x-ray diffraction | A, B, C | — | — |
| 4MR5 | Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazoli ligand… | x-ray diffraction | A | — | — |
| 4MR5 | Crystal structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand… | x-ray diffraction | A | — | — |
| 4MR6 | Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazoli ligand… | x-ray diffraction | A | — | — |
| 4MR6 | Crystal structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand… | x-ray diffraction | A | — | — |
| 4QEU | Crystal structure of BRD2(BD2) mutant in free form | x-ray diffraction | A | — | — |
| 4QEU | Crystal structure of BRD2(BD2) mutant in free form | x-ray diffraction | A | — | — |
| 4QEV | Crystal structure of BRD2(BD2) mutant with ligand ME bound (METHYL (2R)… | x-ray diffraction | A | — | — |
| 4QEV | Crystal structure of BRD2(BD2) mutant with ligand me bound (methyl (2R)… | x-ray diffraction | A | — | — |
| 4QEW | Crystal structure of BRD2(BD2) mutant with ligand ET bound (METHYL (2R)… | x-ray diffraction | A | — | — |
| 4QEW | Crystal structure of BRD2(BD2) mutant with ligand et bound (methyl (2R)… | x-ray diffraction | A | — | — |
| 4UYF | N-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A) | x-ray diffraction | A, B, C | — | — |
| 4UYF | N-terminal bromodomain of human BRD2 with I-BET726 (GSK1324726A) | x-ray diffraction | A, B, C | — | — |
| 4UYG | C-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A) | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4UYG | C-terminal bromodomain of human BRD2 with I-BET726 (GSK1324726A) | x-ray diffraction | A, B, C, D, E, F | — | — |
| 4UYH | N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-((2R,4S)-2-methyl-4-(phenylamino)-6-(4-(piperidin-1-ylme… | x-ray diffraction | A, B, C | — | — |
| 4UYH | N-terminal bromodomain of human BRD2 with 1-((2R,4S)-2-methyl-4… | x-ray diffraction | A, B, C | — | — |
| 5BT5 | Crystal structure of BRD2 second bromodomain in complex with sgc-CBP30 chemical probe | x-ray diffraction | A | — | — |
| 5DFB | Crystal structure of BRD2(BD2) mutant W370F in the free form | x-ray diffraction | A | — | — |
126 records more on the page itself.
Ligands
- CL · Chloride ion · in 19 records
- DQW · (2~{S})-1-[(2~{S})-2-oxidanylpropoxy]propan-2-ol · in 14 records
- SO4 · Sulfate ion · in 11 records
- BUX · 7-chloranyl-2-[(3-chlorophenyl)amino]pyrano[3,4-E][1, 3]oxazine-4,5-dione · in 6 records
- CQF · (6~{R})-~{N}-(4-chlorophenyl)-1-methyl-8-(1-methylpyrazol-4-yl)-5,6-dihydro-4~{H}-[1,2, 4]triazolo[4,3-a][1]benzazepin-6-amine · in 3 records
- G3J · 1-[(2S,4R)-4-[(2-chlorophenyl)amino]-2-methyl-6-(1H-pyrazol-3-yl)-3,4-dihydroquinolin-1(2H)-yl]ethan-1-one · in 3 records
- LDR · phenanthridin-6(5H)-one · in 3 records
- 31O · methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]propanoate · in 2 records
- 31P · methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]butanoate · in 2 records
- 87D · N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]methanesulfonamide · in 2 records
- 8J2 · propan-2-yl ~{N}-[(2~{S},4~{R})-6-(3-acetamidophenyl)-1-ethanoyl-2-methyl-3,4-dihydro-2~{H}-quinolin-4-yl]carbamate · in 2 records
- 9HQ · (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-9-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-~{N}-ethyl-propanamide · in 2 records
- 9HW · (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-8-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-~{N}-ethyl-propanamide · in 2 records
- 9HZ · Methyl (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-8-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-A][1, 4]benzodiazepin-4-yl]pent-4-enoate · in 2 records
- 9J2 · Methyl (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-9-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-A][1, 4]benzodiazepin-4-yl]propanoate · in 2 records
- 9J5 · Methyl (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-9-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-A][1, 4]benzodiazepin-4-yl]butanoate · in 2 records
- 9J8 · (2~{R})-2-[(4~{S})-6-(4-chlorophenyl)-8-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-~{N}-ethyl-pent-4-enamide · in 2 records
- 9JB · 3-[(2~{R})-2-oxidanylpropoxy]-2-[[(2~{R})-2-oxidanylpropoxy]methyl]-2-[[(2~{S})-2-oxidanylpropoxy]methyl]propan-1-ol · in 2 records
- ACE · Acetyl group · in 2 records
- D7Q · 2-((4-acetyl-3-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)methyl)benzoic acid · in 2 records
- G7V · 4-{[(2S,4R)-1-acetyl-2-methyl-6-(1H-pyrazol-3-yl)-1,2, 3,4-tetrahydroquinolin-4-yl]amino}benzonitrile · in 2 records
- H7E · [1-[4-[2-[(4~{S})-6-(4-chlorophenyl)-8-methoxy-1-methyl-4~{H}-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]ethanoylamino]phenyl]piperidin-4-yl]-trimethyl-azanium · in 2 records
- HFU · 5-(1-naphthoyl)-11-methyl-8-((methylsulfonyl)methyl)-4, 5-dihydro-2,3A1,5-triazadibenzo[cd,h]azulen-1(2H)-one · in 2 records
- HWV · N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide · in 2 records
- JFL · 2-(2-cyclobutyl-1~{H}-imidazol-5-yl)-7-[2-(4-fluoranyl-2,6-dimethyl-phenoxy)-5-(2-oxidanylpropan-2-yl) phenyl]-5-methyl-furo[3,2-c]pyridin-4-one · in 2 records
- JFR · 2-(2-cyclopentyl-1~{H}-imidazol-5-yl)-7-[2-(4-fluoranyl-2,6-dimethyl-phenoxy)-5-(2-oxidanylpropan-2-yl)phenyl]-5-methyl-furo[3,2-c]pyridin-4-one · in 2 records
- JGF · ~{N}-[4-[2,4-bis(fluoranyl)phenoxy]-3-[2-(2-cyclobutyl-1~{H}-imidazol-5-yl)-5-methyl-4-oxidanylidene-furo[3, 2-c]pyridin-7-yl]phenyl]ethanesulfonamide · in 2 records
- JGL · ~{N}-[4-[2,4-bis(fluoranyl)phenoxy]-3-[2-(1~{H}-imidazol-5-yl)-5-methyl-4-oxidanylidene-furo[3,2-c]pyridin-7-yl]phenyl]ethanesulfonamide · in 2 records
- K · Potassium ion · in 2 records
- PMW · Methyl (R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butanoate · in 2 records
Experiment against prediction
- 5DFD chain A against the predicted model P25440: TM-score 0.99, RMSD 0.33 Å
- 5O3H chain A against the predicted model P25440: TM-score 0.99, RMSD 0.34 Å
- 5O3H chain A against the predicted model P25440: TM-score 0.99, RMSD 0.34 Å
- 6K04 chain A against the predicted model P25440: TM-score 0.99, RMSD 0.34 Å
- 5O3E chain A against the predicted model P25440: TM-score 0.99, RMSD 0.35 Å
- 5O3E chain A against the predicted model P25440: TM-score 0.99, RMSD 0.35 Å
- 5EK9 chain A against the predicted model P25440: TM-score 0.99, RMSD 0.36 Å
- 5EK9 chain A against the predicted model P25440: TM-score 0.99, RMSD 0.36 Å
- 5DW1 chain B against the predicted model P25440: TM-score 0.99, RMSD 0.37 Å
- 4AKN chain B against the predicted model P25440: TM-score 0.99, RMSD 0.38 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.